Nvidia and Eli Lilly announced a joint, five‑year investment of up to $1 billion to build an AI drug‑discovery laboratory in San Francisco, committing infrastructure, compute and shared talent to accelerate discovery and model development. Lilly said its scientists will work alongside Nvidia engineers to produce large‑scale biological data and train models; Nvidia emphasized platform and chip integration into lab workflows. Separately at JPM, Nvidia outlined additional partnerships with lab suppliers and service providers to embed its AI stack across drug‑discovery pipelines, underscoring the company’s push to move beyond chips into end‑to‑end life‑science infrastructure. The deals formalize a growing industry pattern where pharma finances compute‑heavy AI partnerships to cut discovery timelines and internalize ML capabilities.